A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
The study is being conducted to evaluate the efficacy and safety of SHR-1210 plus FOLFOX4 in subjects with advanced HCC who have never received prior systemic treatment compared to placebo plus FOLFOX4.

The primary study hyposis is that Camrelizumab combined with FOLFOX4 treatment can improve Overall Survival when compared with placebo in combination with FOLFOX4 Regimen.
Advanced Hepatocellular Carcinoma
DRUG: SHR-1210|DRUG: FOLFOX4|DRUG: Placebo
Overall Survival, OS was defined as the time from randomization to death due to any cause, Up to approximately 3 years
Objective Response Rate (ORR) per RECIST 1.1 in all participants, ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: â‰¥30% decrease in the sum of diameters of target lesions) per RECIST 1.1., Up to approximately 6 months|Time to Progression (TTP) per RECIST 1.1 in all participants, Up to approximately 3 years|Duration of Response (DoR) per RECIST 1.1 in all participants, Up to approximately 3 years|Disease Control Rate (DCR) per RECIST 1.1 in all participants, Up to approximately 3 years|Progression-free Survival (PFS) per RECIST 1.1 in all participants, Up to approximately 3 years|AE, Up to approximately 3 years|Overall Survival (OS) rate at 9 months and 12 months, Up to approximately 9 months and 12 months
The study is being conducted to evaluate the efficacy and safety of SHR-1210 plus FOLFOX4 in subjects with advanced HCC who have never received prior systemic treatment compared to placebo plus FOLFOX4.

The primary study hyposis is that Camrelizumab combined with FOLFOX4 treatment can improve Overall Survival when compared with placebo in combination with FOLFOX4 Regimen.